Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
November 2, 2026
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
October 14, 2026
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
October 5, 2026
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
September 24, 2026
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
September 9, 2026
Rezolute to Participate in Upcoming Investor Conferences
September 2, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026